Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

• 主要な著者: Bárbara Lima (著者), Miguel Henriques Abreu (著者), Susana Sousa (著者), Carla Bartosch (著者), Deolinda Pereira (著者)
• フォーマット: 図書
• 出版事項: Elsevier, 2022-04-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinas...